Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial
for chronic schizophrenia patients.
The purpose of this study is to compare efficacy and safety of add-on treatment of sarcosine,
a GlyT-1 inhibitor, and D-serine, an NMDA-glycine site agonist, in chronically stable
schizophrenia patients who have been stabilized with antipsychotics.
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University Hospital
Collaborators:
National Health Research Institutes, Taiwan National Science Council, Taiwan